Navigation Links
Caris Life Sciences Designates MedStar Health a Caris Center of Excellence
Date:5/4/2015

IRVING, Texas, May 4, 2015 /PRNewswire/ -- Caris Life Sciences®, a leading biotechnology company focused on fulfilling the promise of precision medicine, today announced the designation of MedStar Health as a center of excellence site in the Caris Centers of Excellence for Precision Medicine Network™ (Network). MedStar has 10 hospitals in Maryland and the Washington, D.C., region, and is a leader in oncology research and treatment, with MedStar Georgetown University's Lombardi Comprehensive Cancer Center being the only National Cancer Institute-designated center in the region and one of only 41 in the country.

"We are very pleased to welcome MedStar to the COE Network, especially as MedStar has such a deep commitment to the most advanced cancer diagnosis and therapy regimens," said David D. Halbert, Chairman and CEO of Caris Life Sciences. "We are beginning to see a groundswell of support for the Caris Centers of Excellence for Precision Medicine Network and the development of standardized tumor profiling guidelines to improve treatment outcomes and reduce the financial burden of cancer care."

As a Network member, MedStar Health will actively participate in the development of standards of care and best practices for integrating and using molecular profiling in oncology practice to increase patient access to personalized medicine in clinical settings. MedStar Health will also leverage Caris' multiple-technology tumor profiling service, Caris Molecular Intelligence®, to enable the practice of precision medicine by identifying therapy options and clinical trial opportunities based on the unique characteristics of a patient's tumor.

"Molecular profiling is advancing at a very rapid rate, as are therapeutic mechanisms to target both genetic and proteomic mutations," said Stephen R.T. Evans, M.D., MedStar's Executive Vice President for Medical Affairs and the health system's Chief Medical Officer. "We are pleased to be the first system to join the Caris COE Network effort and look forward to collaborating with other healthcare organizations to provide increasingly powerful and timely information to aid physicians in making complex cancer therapy decisions."

Caris Molecular Intelligence, a service that correlates molecular data from a tumor with biomarker and drug associations from the latest clinical and scientific cancer literature, is the key technology platform used across the Network to enable the delivery of precision medicine. This information is used to help inform treatment decisions by identifying therapies that have the potential to be most effective and to rule out those that are less likely to work based on the unique molecular characteristics of an individual patient's cancer. The Caris Molecular Intelligence system uses multiple technology platforms combined with sophisticated bioinformatics to develop clinically actionable reports for more than 70,000 patients to date.

About Caris Life Sciences®
Caris Life Sciences® is a leading biotechnology company focused on fulfilling the promise of precision medicine through quality and innovation. Caris Molecular Intelligence®, the company's healthcare information and comprehensive tumor profiling service with more than 70,000 patients profiled, provides oncologists with the most potentially clinically actionable treatment options available to personalize cancer care today. Using a variety of advanced profiling technologies to assess relevant biological changes in each patient's tumor, Caris Molecular Intelligence connects biomarker data generated from a tumor with biomarker-drug associations supported by evidence in the relevant clinical literature. Since 2009, Caris has tracked clinical and outcome data for certain patients undergoing tumor molecular profiling, for which Caris has observed that patients treated with drugs consistent with their molecular profile show a significant increase in overall survival. The company is developing its Carisome® TOP™ technology, a revolutionary and proprietary blood-based platform for the development of novel therapeutics, drug delivery and drug target identification. The technology is also being developed for diagnosis, prognosis, and theranosis of cancer and other complex diseases. Headquartered in Irving, Texas, Caris Life Sciences offers services throughout Europe, the U.S., Australia and other international markets. To learn more, please visit www.CarisLifeSciences.com


'/>"/>
SOURCE Caris Life Sciences
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. The Caristix HL7 Survival Guide: Understand the Complete Interface Lifecycle
2. Caris Life Sciences Receives Tumor Profiling Industrys First ISO 15189 Medical Laboratory Accreditation
3. Caris Life Sciences Collaborates with GenoSpace to Enhance Data Mining Capabilities to Advance the Molecular Understanding of Cancer
4. Caris Life Sciences Selects IBM to Accelerate Use of Molecular Profiling in Cancer Treatment Selection
5. Caris Life Sciences Multiplatform Tumor Profiling Helps to Identify Potential Predictive Biomarkers in Renal Cell Carcinoma
6. Caris Life Sciences Multiplatform Tumor Profiling Enhances Understanding of Molecular Drivers and Treatment Selection in Uterine Carcinomas
7. Caris Life Sciences and COTA Enter Collaboration to Measure Clinical and Economic Impact of Evidenced-Based Drug Selection for Precision Medicine in Oncology
8. Amgen To Present At The UBS Global Life Sciences Conference
9. Ambit Biosciences Announces Presentations of Data from Clinical Investigations of Quizartinib at the Annual Meeting of the American Society of Clinical Oncology
10. Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support
11. Neurocrine Biosciences to Present At The Deutsche Bank 38th Annual dbAccess Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2020)... ... August 31, 2020 , ... Continuing ... - a broad-spectrum sanitization, disinfection and deodorization provider - is proud to announce ... and disinfecting services for businesses and residents throughout the area. , Germinator provides ...
(Date:8/27/2020)... ... August 27, 2020 , ... InfoMC, ... the successful completion of their 2020 System and Organizational Controls (SOC) 1® Type ... assessment and MARS-E compliance assessment. These achievements reflect their long-standing commitment to privacy, ...
(Date:8/27/2020)... ... 27, 2020 , ... Bridge To A Cure Foundation announces the appointment of ... pediatric neuro-oncologist who serves on the Board of Directors at The Preston Robert Tisch ... School. , Internationally recognized, Dr. Friedman is a widely published author of more than ...
Breaking Medicine Technology:
(Date:8/31/2020)... PITTSBURGH (PRWEB) , ... August 31, 2020 , ... ... Allegheny Health Network (AHN), are joining biomedical engineers from Carnegie Mellon University (CMU) ... alternative for cardiac patients who have undergone open heart surgery. , The AGH/CMU ...
(Date:8/31/2020)... ... August 31, 2020 , ... ... N95 face masks to medical first responders across the United States. Since the ... of personal protective equipment (PPE) medical centers , hospitals , ...
(Date:8/31/2020)... ... August 31, 2020 , ... Colorado ... through high-quality, career-relevant, and affordable online education – is proud to announce its ... Among the first of its kind in the nation, the 60-credit hour program ...
(Date:8/31/2020)... ... 31, 2020 , ... A Cure for Covid-19 “PTS” with Mediation & Hypnosis , At ... a state of panic, experiencing deep anxiety, immense stress, and right now are needing serious ... when most people on the planet are experiencing a great degree of emotional discomfort, be ...
(Date:8/31/2020)... ... August 31, 2020 , ... Bonde Innovations, ... patients with advanced heart failure, today announced that the company has been awarded ... $555,358 from the National Heart, Lung, and Blood Institute of the National Institutes ...
Breaking Medicine News(10 mins):